Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to:
1. Evaluate the safety and efficacy of a steroid eye drop (Lotemax) in patients who have
been diagnosed with graft-versus-host disease (GVHD), which is a complication that may
occur after bone marrow transplant where the newly transplanted material attacks the
patient's body and may cause eye dryness.
2. Assess the safety and efficacy of Lotemax in decreasing the eye's reaction to the
process in GVHD before the patient undergoes bone marrow transplant.
3. Compare how well Lotemax works in decreasing the process in GVHD with an
immunosuppressive eye drop (Restasis), which has been commonly used in the treatment of
this condition.